Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative disorders. Despite advancements in screening and management strategies, challenges persist in evaluating DR progression, identifying reliable biomarkers, and developing targeted therapies. Recent insights into the role of lipoproteins, epigenetics, and systemic inflammatory pathways in DR pathogenesis have opened new avenues for research and therapeutic interventions. Objective This review aims to provide a comprehensive update on the pathogenesis of DR, highlighting emerging biomarkers and epigenetic factors involved in disease progression. In addition, the efficacy of novel therapeutic approaches targeting key signaling pathways in both preclinical and clinical settings is explored. Methods A comprehensive literature review was conducted using multiple public databases, including PubMed, Scopus, Google Scholar, and the National Library of Medicine. Relevant studies published in the past decade were analyzed to assess advancements in DR pathophysiology, biomarker discovery, epigenetic implications, and emerging therapeutic strategies. Key findings were synthesized to present an integrated perspective on the evolving landscape of DR research and management. Results Our analysis reveals that DR pathogenesis involves complex neurovascular interactions, oxidative stress, and hyperglycemia‐induced epigenetic modifications. Lipoprotein metabolism and menopausal hormonal changes were found to influence DR progression, emphasizing the need for personalized risk assessments. The review further highlights the role of circulating blood biomarkers, omega‐3 fatty acids, microRNAs, and inflammatory cytokines as potential indicators of disease severity. In addition, novel therapeutic approaches, including anti‐VEGF agents, neuroprotective strategies, and epigenetic modulators, have shown promising results in preclinical and early clinical studies. Targeting multiple signaling pathways, including VEGF, Wnt/β‐catenin, and inflammatory cascades, holds significant potential for improving DR outcomes. Conclusion Advancements in biomarker research and epigenetic regulation provide significant avenues pertinent to DR pathogenesis and progression. The integration of molecular and clinical approaches is essential for developing targeted therapies that address both ocular and systemic implications of DR. Future research should focus on translating these findings into personalized treatment strategies to enhance patient outcomes and prevent vision loss.
Huang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: